

10/636,155

***** STN Columbus *****

FILE 'HOME' ENTERED AT 10:37:29 ON 15 SEP 2004

=> file reg

=>


Uploading 10636155.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

L3 13 SEA SSS FUL L1

=> file ca

=> s l3

L4 844 L3

=> s l3/prep

844 L3

3191721 PREP/RL

L5 25 L3/PREP

(L3 (L) PREP/RL)

=> file reg

=>

Uploading 1.str


L6 STRUCTURE UPLOADED

=> d l6


L6 HAS NO ANSWERS

L6 STR

L8 ANSWER 1 OF 10 CA COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 140:390934 CA
 TITLE: Recoverable, Reusable, Highly Active, and Sulfur-Tolerant Polymer Incorporated Palladium for Hydrogenation
 AUTHOR(S): Okamoto, Kuniaki; Akiyama, Ryo; Kobayashi, Shu
 CORPORATE SOURCE: Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, 113-0033, Japan
 SOURCE: Journal of Organic Chemistry (2004), 69(8), 2871-2873
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A new type of immobilized palladium, PI (polymer incorporated) Pd, prepd. from Pd(PPh₃)₄ and the copolymer has been developed. The excellent activity of PI Pd has been demonstrated in hydrogenation of various olefins, benzyl ethers, and nitro and arom. compds. PI Pd is tolerant under high pressure and high temp. and can be recovered and reused several times without loss of activity even under harsh conditions. Moreover, PI Pd is highly resistant to poisoning by sulfur.
 IT 136401-69-9
 RL: RCT (Reactant); RACT (Reactant or reagent) (prepn. and use of a recoverable, reusable, highly active, and sulfur-tolerant polymer incarcerated palladium catalyst for hydrogenation reactions)
 RN 136401-69-9 CA
 CN 2,4-Thiazolidinedione.
 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]ne]-, (5Z)- (9CI) (CA INDEX NAME)
 Double bond geometry as shown.




L8 ANSWER 2 OF 10 CA COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 140:217543 CA
 TITLE: Optimization of the Reduction of a 5-Benzylidenethiazolidine-2,4-dione Derivative Supported by the Reaction Response Surface Analysis: Synthesis of Pioglitazone Hydrochloride
 AUTHOR(S): Les, Andrzej; Pucko, Wieslaw; Szelegowski, Wieslaw
 CORPORATE SOURCE: Pharmaceutical Research Institute, Warsaw, 01-793, Pol.
 SOURCE: Organic Process Research & Development (2004), 8(2), 157-162
 CODEN: OPRDFK; ISSN: 1083-6160
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Significant improvements were made in the C:C bond redn. of the (benzylidene)thiazolidinedione 1, an intermediate in the synthesis of pioglitazone hydrochloride. A reaction response surface anal. was applied to a series of expts. carried out under various conditions (temp., time, amt. of a catalyst and redn. reagents, purifn. of the substrate).
 IT 111025-46-8P, Pioglitazone 144809-28-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (optimization studies for the redn. of (benzylidene)thiazolidinedione deriv., the intermediate in the prepn. of pioglitazone hydrochloride, supported by the reaction response surface anal.)
 RN 111025-46-8 CA
 CN 2,4-Thiazolidinedione.
 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]ne]- (9CI) (CA INDEX NAME)

L8 ANSWER 1 OF 10 CA COPYRIGHT 2004 ACS on STN (Continued)
 IT 111025-46-8P, Pioglitazone
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. and use of a recoverable, reusable, highly active, and sulfur-tolerant polymer incarcerated palladium catalyst for hydrogenation reactions)
 RN 111025-46-8 CA
 CN 2,4-Thiazolidinedione.
 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]ne]- (9CI) (CA INDEX NAME)



PAGE 1-A


Et

PAGE 2-A

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L8 ANSWER 2 OF 10 CA COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




Et

PAGE 2-A

RN 144809-28-9 CA
 CN 2,4-Thiazolidinedione.
 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]ne]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 10 CA COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




Et

PAGE 2-A

IT 112529-15-4P, Pioglitazone hydrochloride
 RL: SPN (Synthetic preparation), PREP (Preparation)
 (optimization studies for the redn. of (benzylidene)thiazolidinedione deriv., the intermediate in the prepn. of pioglitazone hydrochloride, supported by the reaction response surface anal.)
 RN 112529-15-4 CA
 CN 2,4-Thiazolidinedione,
 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-
 , monohydrochloride (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 10 CA COPYRIGHT 2004 ACS on STN (Continued)



● HCl

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L8 ANSWER 3 OF 10 CA COPYRIGHT 2004 ACS on STN
 140:111409 CA
 ACCESSION NUMBER:
 TITLE: A novel process to prepare pioglitazone via several novel intermediates.
 INVENTOR(S): Pandey, Bipin; Lohray, Vidya Bhushan; Lohray, Braj Bhushan
 PATENT ASSIGNEE(S): Cadila Healthcare Limited, India
 SOURCE: PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007490	A2	20040122	WO 2003-IN241	20030715
WO 2004007490	A3	20040325		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IE, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LJ, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GM, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IN 2002-MU648 A 20020716

OTHER SOURCE(S): CASREACT 140:111409; MARPAT 140:111409
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The present invention discloses a novel and general process to prep. various pyridine substituted 5-[4-[2-(alkyl substituted pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione deriva. of general formula I (R = alkyl), and their pharmaceutically acceptable salts. The present invention esp. provides a novel process to prep. pioglitazone hydrochloride [R = 5-ethyl], via novel intermediates, i.e. II and III. This process involves lesser no. of steps with high yields and uses key solid intermediates, which are operationally simple, and therefore offers opportunities for better com. viability.

IT 111025-46-8P 144809-28-9P
 RL: IMP (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of pioglitazone via several novel intermediates)

RN 111025-46-8 CA
 CN 2,4-Thiazolidinedione,
 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-
 (9CI) (CA INDEX NAME)

L8 ANSWER 3 OF 10 CA COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




Et

PAGE 2-A

RN 144809-28-9 CA
 CN 2,4-Thiazolidinedione,
 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-
 ne]- (9CI) (CA INDEX NAME)

L8 ANSWER 3 OF 10 CA COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

Et

IT 112529-15-4P
 RL: IMP (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of pioglitazone via several novel intermediates)
 RN 112529-15-4 CA
 CN 2,4-Thiazolidinedione,
 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-
 , monohydrochloride (9CI) (CA INDEX NAME)

L8 ANSWER 3 OF 10 CA COPYRIGHT 2004 ACS on STN (Continued)



● HCl

L8 ANSWER 4 OF 10 CA COPYRIGHT 2004 ACS on STN


ACCESSION NUMBER: 140:59637 CA
 TITLE: A process for the production of 5-[[4-[2-(5-ethyl-2-pyridylethoxy)benzyl]-2,4-thiazolidinedione hydrochloride
 INVENTOR(S): Adiyaman, Mustafa; Guner, Didem; Yurdakul, Aytil; Ridvanoglu, Nurten
 PATENT ASSIGNEE(S): EOS Eczacibasi Ozgun Kimyasal Urunler Sany ve Ticaret
 SOURCE: A.S., Turk.
 PCT Int. Appl., 15 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004/00810	A1	20031231	WO 2002-TR25	20020619
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AE, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPL. INFO.:		WO 2002-TR25 20020619		

OTHER SOURCE(S): CASREACT 140:59637; MARPAT 140:59637
 AB 5-[[4-[2-(5-Ethyl-2-pyridylethoxy)benzyl]-2,4-thiazolidinedione hydrochloride is prepd. in high yield and selectivity by the esterification of 2-(5-ethyl-2-pyridyl)ethanol with methanesulfonyl chloride to give 2-(5-ethyl-2-pyridyl)ethyl methanesulfonate which is then etherified with 4-hydroxybenzaldehyde in the presence of KI to give 4-[2-(5-ethyl-2-pyridyl)ethoxy]benzaldehyde which is then subjected to an Aldol condensation with 2,4-thiazolidinedione in the presence of piperidine to give 5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzylidene]-2,4-thiazolidinedione which is reduced with sodium borohydride to give 5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione, which, upon salification with hydrogen chloride gives 5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride.
 IT 111025-46-8P 144809-28-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (in a process for the prodn. of 5-[[4-[2-(5-ethyl-2-pyridylethoxy)benzyl]-2,4-thiazolidinedione hydrochloride)
 RN 111025-46-8 CA
 CN 2,4-Thiazolidinedione,
 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-
 (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 10 CA COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




Et

PAGE 2-A

RN 144809-28-9 CA
 CN 2,4-Thiazolidinedione,
 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-
 ne]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

Et

IT 112529-15-49

RL: SPN (Synthetic preparation); PREP (Preparation)
 (process for the prodn. of
 5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-
 thiazolidinedione hydrochloride])
 RN 112529-15-4 CA
 CN 2,4-Thiazolidinedione,
 5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]methyl]-
 monohydrochloride (9CI) (CA INDEX NAME)

L8 ANSWER 5 OF 10 CA COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 139:86976 CA
 TITLE: Catalytic hydrogenation of exocyclic double bonds in
 production of thiazolidinedione antihyperglycemics
 INVENTOR(S): Dolitzky, Ben-zion
 PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva
 Pharmaceuticals Usa, Inc.
 SOURCE: PCT Int. Appl., 22 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003053367	A2	20030703	WO 2002-US41278	20021220
WO 2003053367	A3	20030904		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003153765	A1	20030814	US 2002-324928	20021220
PRIORITY APPLN. INFO.:			US 2001-342437P	P 20011220

OTHER SOURCE(S): CASREACT 139:86976

AB A method of catalytic hydrogenation of the exocyclic double bond of a penultimate thiazolidinedione precursor comprises (a) providing a soln. of the penultimate thiazolidinedione precursor in a high capacity solvent, (b) combining the soln. with a supported metal hydrogenation catalyst in a reactor, and (c) exposing the mixt. of the soln. and the hydrogenation catalyst to hydrogen gas. The method is used in prodn. of a thiazolidinedione antihyperglycemic drug, such as pioglitazone, troglitazone, and rosiglitazone. Thus, 5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]methylene]-2,4-thiazolidinedione (50 g), DMF (250 mL) and Pd/C (50 g) were charged into an autoclave. The hydrogenation was carried out at 3 atm of H₂ pressure at 50.degree. for 72 h to convert 68.5% of the starting material and afford pioglitazone contg. 3.5% of impurities.

IT 111025-46-8P, Pioglitazone
 RL: IMF (Industrial manufacture); PREP (Preparation)
 (catalytic hydrogenation of exocyclic double bonds in prodn. of thiazolidinedione antihyperglycemics)

RN 111025-46-8 CA
 CN 2,4-Thiazolidinedione,
 5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]methyl]-
 (9CI) (CA INDEX NAME)




● HCl

REFERENCE COUNT: 5
 FORMAT

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE

PAGE 1-A



Et


PAGE 2-A

IT 144809-28-9

RL: RCT (Reactant); RACT (Reactant or reagent)
 (catalytic hydrogenation of exocyclic double bonds in prodn. of thiazolidinedione antihyperglycemics)
 RN 144809-28-9 CA
 CN 2,4-Thiazolidinedione,
 5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]methyl]-
 ne]- (9CI) (CA INDEX NAME)

L8 ANSWER 5 OF 10 CA COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

Et

L8 ANSWER 6 OF 10 CA COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 137:169513 CA

TITLE: Method for preparing compounds derived from thiazolidinedione, oxazolidinedione or hydantoin
 Bulliard, Michel; Derrien, Yvon; Pintus, Tony
 Ppg-Sipre, Fr.
 SOURCE: PCT Int. Appl., 15 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064577	A2	20020822	WO 2002-FR571	20020214
WO 2002064577	A3	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2820741	A1	20020816	FR 2001-2010	20010214
FR 2820742	A1	20020816	FR 2001-5206	20010417
EP 1360179	A2	20031112	EP 2002-704834	20020214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002006967	A	20040309	BR 2002-6967	20020214
JP 2004520401	T2	20040708	JP 2002-564510	20020214
US 2004059121	A1	20040325	US 2003-636155	20030807
PRIORITY APPL. INFO.:				FR 2001-2010 A 20010214
				FR 2001-5206 A 20010417
				WO 2002-FR571 W 20020214

OTHER SOURCE(S):
GI


CASREACT 137:169513; MARPAT 137:169513



AB Title compds. I [O, Q1 = O, S; R1, R2 = H, alkyl, cycloalkyl, alkylaryl].

L8 ANSWER 6 OF 10 CA COPYRIGHT 2004 ACS on STN (Continued)
 arylalkyl, optionally substituted by alkyl, alkoxy, aryloxy, halogen, hydroxy, sulfino, sulfonyl, amino; R1, R4 = H] were prepd. by reducing I [R3R4 = bond] with HCO2H in presence of a transition metal catalyst, and optionally a cosolvent. Thus, I [Q = S, Q1 = O, R1 = H, R2 = 4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl (Q2), R3R4 = bond] was treated with HCO2H and H in presence of Pd-C at 75-80.degree. for 6 h to give 97.4% pioglitazone [I, Q = S, Q1 = O, R1 = R3 = R4 = H, R2 = Q2].
 IT 111025-46-8P, Pioglitazone
 RL: IMP (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of thiazolidinediones, oxazolidinediones or hydantoin by redn. of their alkylidene derivs.)
 RN 111025-46-8 CA
 CN 2,4-Thiazolidinedione,
 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

Et

L8 ANSWER 6 OF 10 CA COPYRIGHT 2004 ACS on STN (Continued)
 nel- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


Et

IT 144809-26-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of thiazolidinediones, oxazolidinediones or hydantoin by redn. of their alkylidene derivs.)
 RN 144809-26-9 CA
 CN 2,4-Thiazolidinedione,
 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-
 (9CI) (CA INDEX NAME)

LB ANSWER 7 OF 10 CA COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 128:127942 CA
 TITLE: Process for preparing 4-(2-(2-pyridyl)ethoxy)benzaldehyde derivatives
 INVENTOR(S): Saito, Yuzuru; Mizutune, Hideya; Yamashita, Makoto
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: Eur. Pat. Appl., 15 pp.
 CODEV: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 816340	A1	19980107	EP 1997-304554	19970626
EP 816340	B1	20030423		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 5952509	A	19990914	US 1997-880638	19970623
CA 2208878	AA	19971227	CA 1997-2208878	19970626
CA 2208878	C	20020820		
JP 10072438	A2	19980317	JP 1997-170637	19970626
JP 3256841	B2	20020218		
AT 238202	E	20030515	AT 1997-304554	19970626
PT 816340	T	20030829	PT 1997-304554	19970626
ES 2191811	T3	20030916	ES 1997-304554	19970626
US 6100403	A	20000808	US 1999-292384	19990412
PRIORITY APPLN. INFO.:				JP 1996-167862 A 19960627
				US 1997-880638 A3 19970623


OTHER SOURCE(S): MARPAT 128:127942
 GI



AB 4-(2-(2-Pyridyl)ethoxy)benzaldehydes, which are useful as starting compds. for producing thiazolidinedione deriva. with hypoglycemic and hypolipidemic activities, are prepd. by treating a 2-(2-pyridyl)ethyl sulfonate with 4-HOC6H4CHO in a lower alc. in the presence of an alkali metal or alk. earth metal carbonate. Thus, 2-(5-ethyl-2-pyridyl)ethanol was converted to its mesylate and treated with 4-HOC6H4CHO and K2CO3 in EtOH-PhMe for 5 h at 80 degree. to give 78.9% 4-(2-(5-ethyl-2-pyridyl)ethoxy)benzaldehyde. This compd. was treated with 2,4-thiazolidinedione to give the benzylidenethiazolidinedione I in 61.4% overall yield from 2-(5-ethyl-2-pyridyl)ethanol.

LB ANSWER 7 OF 10 CA COPYRIGHT 2004 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A

Et

IT 112529-15-4P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 4-(2-(2-pyridyl)ethoxy)benzaldehyde deriva.)
 RN 112529-15-4 CA
 CN 2,4-Thiazolidinedione,
 5-[[4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl]methyl]-
 , monohydrochloride (9CI) (CA INDEX NAME)




● HCl

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS

LB ANSWER 7 OF 10 CA COPYRIGHT 2004 ACS on STN (Continued)
 IT 144809-28-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of 4-(2-(2-pyridyl)ethoxy)benzaldehyde deriva.)
 RN 144809-28-9 CA
 CN 2,4-Thiazolidinedione,
 5-[[4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl]methyl]-
 ne]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

Et


IT 111025-46-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of 4-(2-(2-pyridyl)ethoxy)benzaldehyde deriva.)
 RN 111025-46-8 CA
 CN 2,4-Thiazolidinedione,
 5-[[4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl]methyl]-
 (9CI) (CA INDEX NAME)

LB ANSWER 7 OF 10 CA COPYRIGHT 2004 ACS on STN (Continued)
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L8 ANSWER 8 OF 10 CA COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 119:249944 CA
 TITLE: Regioselective reduction of substituted
 5-(methylene)thiazolidinediones
 INVENTOR(S): Huber, Joel Edward
 PATENT ASSIGNEE(S): Upjohn Co., USA
 SOURCE: PCT Int. Appl., 21 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9313095	A1	19930708	WO 1992-US10329	19921204
W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
AU 9332310	A1	19930728	AU 1993-32310	19921204
EP 618915	A1	19941012	EP 1993-900732	19921204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07502530	T2	19950316	JP 1992-511663	19921204
JP 2766730	B2	19980618		
CA 2122712	C	19990921	CA 1992-2122712	19921204
US 5585495	A	19961217	US 1994-397130	19940617
PRIORITY APPLN. INFO.:			US 1991-811103	A2 19911220
			WO 1992-US10329	A 19921204


OTHER SOURCE(S): CASREACT 119:249944; MARPAT 119:249944
 GI



AB The title process comprises producing compds. I (X1 = org. residue), by

L8 ANSWER 8 OF 10 CA COPYRIGHT 2004 ACS on STN (Continued)
 regioselectively reducing compds. II with a Co ion, a ligand (e.g., dimethylglyoxime, 2,2'-bipyridyl, 1,10-phenanthroline), and a reducing agent (e.g., NaBH4, LiBH4, KBH4, etc.). This process is conducted at -20.degree. to -45.degree. and overcomes many of the problems of prior art redn. processes which required troublesome high-pressure hydrogenations using Pd/C catalysts, and is esp. suited for the prepn. of Pioglitazone hydrochloride (III). Thus, thiazolidinedione IV was slurried in water and 50% aq. NaOH soln., dimethylglyoxime, powd. blue indicating silica gel (contg. approx. 0.7% CoCl2) added, NaBH4 added, and DMF added. The intermediate III free base was reacted with HCl in AcOEt, producing III.

IT 111025-46-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and reaction of, with hydrochloric acid)
 RN 111025-46-8 CA
 CN 2,4-Thiazolidinedione,
 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-
 (9CI) (CA INDEX NAME)




PAGE 1-A

L8 ANSWER 8 OF 10 CA COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

IT 112529-15-4P, Pioglitazone hydrochloride
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, by regioselective redn.)
 RN 112529-15-4 CA
 CN 2,4-Thiazolidinedione,
 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 144809-28-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (regioselective redn. of)
 RN 144809-28-9 CA
 CN 2,4-Thiazolidinedione,
 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-
 ne) (9CI) (CA INDEX NAME)

L8 ANSWER 8 OF 10 CA COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

Et


L8 ANSWER 9 OF 10 CA COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 118:6971 CA
 TITLE: Preparation of ether-containing 2,4-thiazolidinedione derivatives
 INVENTOR(S): Arita, Miichiro; Mizuno, Yukio
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: Eur. Pat. Appl., 7 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 506273	A2	19920930	EP 1992-302233	19920316
EP 506273	AJ	19930113		
EP 506273	B1	19950531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE				
CA 2063851	AA	19920926	CA 1992-2063851	19920324
CA 2063851	C	20030624		
JP 05112483	A2	19930507	JP 1992-66368	19920324
US 5554758	A	19960910	US 1995-474133	19950607
			JP 1991-60208	A 19910325
PRIORITY APPL. INFO.:				
			US 1992-855798	B1 19920323
			US 1993-121291	B1 19930915
			US 1994-352184	B1 19941201

OTHER SOURCE(S): MARPAT 118:6971
 AB Title compds. ACH2CH2OB (A = aryl, R1CO, R2CH:CH, wherein R1, R2 = aliph. hydrocarbyl, arom. hydrocarbyl, heterocyclyl, arylalkyl, alicyclyl; B = aryl) useful as intermediates for, among others, medicines, are prepd. by reacting ACH2CH2X (X = leaving group) with MOB (M = alkali metal, alk. earth metal) in a nonaq. solvent. 2-(5-Ethyl-2-pyridyl)ethyl methanesulfonate (prepn. given) and 4-(OCH)C6H4OK were refluxed to give 4-[[2-(5-ethyl-2-pyridyl)ethoxy]benzaldehyde. This was condensed with 2,4-thiazolidinedione to give the benzylidene deriv., which was hydrogenated to give 5-[[4-[[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione, which is active against diabetes (no data).
 IT 144809-28-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and hydrogenation of)
 RN 144809-28-9 CA
 CN 2,4-Thiazolidinedione,
 5-[[4-[[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]methyl-
 ne]- (9CI) (CA INDEX NAME)

L8 ANSWER 9 OF 10 CA COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




Et

PAGE 2-A

IT 111025-46-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as antidiabetic)
 RN 111025-46-8 CA
 CN 2,4-Thiazolidinedione,
 5-[[4-[[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]methyl]-
 (9CI) (CA INDEX NAME)

L8 ANSWER 9 OF 10 CA COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



Et


PAGE 2-A

L8 ANSWER 10 OF 10 CA COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 115:159025 CA
 TITLE: Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds
 AUTHOR(S): Momose, Yu; Meguro, Kanji; Ikeda, Hitoshi; Hatanaka, Chitoshi; Oi, Satoru; Sohda, Takashi
 CORPORATE SOURCE: Res. Dev. Div., Takeda Chem. Ind., Ltd., Osaka, 532, Japan
 SOURCE: Chemical & Pharmaceutical Bulletin (1991), 39(6), 1440-5
 CODEN: CPBTAL; ISSN: 0009-2363
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The prepn. of pioglitazone (I) analogs II (R = H, 3-, 5-, 6-Me, 5-Et; R1 = H, Me; X = CH, N) and III (n = 1, 2; X1 = S, NH; Y = O, S; Z = NH, NCH2CO2H, S) from phenyl- and pyridylethanol IV and the investigation of their structure activity relationships as antidiabetic and hypolipemic agents are reported. III (X1 = S; Y = O; Z = NH) were equipotent to I, however, other compds. were less active than I. Catalytic hydrogenation of III (R = 5-Et; R1 = H; n = 2; X = S; Y = O; Z = NH) was found to be a convenient route to I.
 IT 136401-69-9P 136401-70-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and hypoglycemic and hypolipemic activity of)
 RN 136401-69-9 CA
 CN 2,4-Thiazolidinedione,
 5-[[4-[[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]methyl-
 ne]-, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 136401-70-2 CA
 CN 2,4-Thiazolidinedione,
 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methylene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 111025-46-8P, Pioglitazone
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and hypoglycemic and hypolipidemic activity of)
 RN 111025-46-8 CA
 CN 2,4-Thiazolidinedione,
 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methylene]-
 (9CI) (CA INDEX NAME)



Et

10/636,155

=> d his

(FILE 'HOME' ENTERED AT 10:37:29 ON 15 SEP 2004)

FILE 'REGISTRY' ENTERED AT 10:37:35 ON 15 SEP 2004

L1 STRUCTURE UPLOADED

L2 0 S L1 SAM

L3 13 S L1 FULL

FILE 'CA' ENTERED AT 10:37:57 ON 15 SEP 2004

L4 844 S L3

L5 25 S L3/PREP

FILE 'REGISTRY' ENTERED AT 10:38:39 ON 15 SEP 2004

L6 STRUCTURE UPLOADED

L7 3 S L6 FULL

FILE 'CA' ENTERED AT 10:39:01 ON 15 SEP 2004

L8 10 S L5 AND L7

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 10:39:59 ON 15 SEP 2004